Effects of Lactose on Fecal Microflora (ELM)

This study has been completed.
Sponsor:
Collaborator:
Danone Institute International
Information provided by:
Sir Mortimer B. Davis - Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT00599859
First received: January 10, 2008
Last updated: September 18, 2009
Last verified: September 2009
  Purpose

The genetics of lactase divides the population into 2 phenotypes: Those who can(LP) and those who cannot(LNP)digest lactose. This division may help modify disease risks according to geographic population distribution. At least some of the putative mechanism of risk modification may relate to an effect of undigested lactose on lower intestinal bacteria. The effect may provide for support of beneficial microbes. The amount of lactose reaching the colon is made easier in LNP than LP subjects who have to consume larger amounts to have meaningful spillover into the lower bowel.The current study examines whether there are quantifiable qualitative fecal bacterial differences to a standard intake of lactose(milk sugar)between these 2 different phenotypic populations. Finding of differences would lend support to the notion that for some diseases LP and LNP subjects face different risks even in an area of uniform disease risk if they consume lactose (found in dairy foods).

The primary end point is comparison of 4 groups of specific bacteria between LP and LNP participants before and after 2 weeks of lactose(in powder form mixed in water) consumption. Classification is based on genetic analysis and secondarily on breath hydrogen results. Results are compared within groups.

The secondary outcome is comparison of 4 groups of bacteria between LP and LNP subjects against each group of stool samples obtained on the first visit. Results are obtained between groups.

Additional information and other secondary outcomes are to evaluate any relationship between diet intake and the 4 groups of bacteria on the first visit

Another outcome will be to compare within groups any effect of lactose consumption on insulin and glucose levels within the 2 groups.


Condition Intervention
Lactose Intolerance
Dietary Supplement: lactose

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Differential Biologic Impact of Lactose Consumption in Lactase Persistent and Non-persistent Populations: Evaluation of Microflora and Insulin/Glycemic Response

Resource links provided by NLM:


Further study details as provided by Sir Mortimer B. Davis - Jewish General Hospital:

Primary Outcome Measures:
  • bacterial differences within the 2 groups between the 2 weeks of lactose ingestion [ Time Frame: 2 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • bacterial differences between the 2 groups on comparison of first stool sample [ Time Frame: 1 day ] [ Designated as safety issue: No ]

Enrollment: 57
Study Start Date: September 2006
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Participants in arm 1 are grouped as lactose digesters based on genetic analysis and breath hydrogen results. In discrepant cases the genetic status is accepted. Arm 1 is initially withdrawn from dairy foods(lactose) and then asked to consume lactose 50g in divided doses mixed in water for 2 weeks.
Dietary Supplement: lactose
consumption of 50g lactose/day in 2 divided doses mixed in water.
Active Comparator: 2
Arm 2 are lactose maldigesters: 2 interventions are a. withdrawal from lactose for 2 weeks and b. consumption of 50g lactose in divided doses mixed in water for a 2 week period.
Dietary Supplement: lactose
consumption of lactose 50g/day in 2 divided doses mixed in water

Detailed Description:

Healthy volunteers between the ages of 18 and 49 are recruited.

  1. Each participant fills a lactose targetting diet questionnaire(3 day recall).
  2. A 50g lactose challenge tets is administered,breath hydrogen and symptoms are recorded for 4.5hrs.
  3. Blood is drawn for analysis of lactase genetic status.
  4. A stool sample is collected(10-15g)and analysed fo total anaerobes, enterococci, bifidobacteria and lactobacilli.
  5. All subjects are withdrawn from dairy foods(calcium replacement suggested in diet) for 2 weeks and are aked to return to repeat parts 2 and 4.
  6. A voluntary segment has glucose and insulin measured for 4 hrs via an indwelling venous catheter.
  7. Subjects are asked to consume 50g lactose in divided doses for 2 further weeks
  8. At the end they return and repeat sections 2 and 4 for the third time.
  9. Participants who volunteered to have glucose and insulin measured repeat this segment of the study as well.
  Eligibility

Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 18-49 yr old male or female.
  • Healthy except may take chronic thyroid or hypertension medication.

Exclusion Criteria:

  • Pregnancy
  • Antibiotics in last 6 weeks
  • Any active illness.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00599859

Locations
Canada, Quebec
Sir Mortimer B Davis General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Sir Mortimer B. Davis - Jewish General Hospital
Danone Institute International
Investigators
Principal Investigator: Andrew Szilagyi, MD SMBD Jewish General Hospital
  More Information

Publications:
Responsible Party: Andrew Szilagyi MD, SMBD Jewish General Hospital , McGill university
ClinicalTrials.gov Identifier: NCT00599859     History of Changes
Other Study ID Numbers: GIA-05-01, Danone Institute Mtl, Canada
Study First Received: January 10, 2008
Last Updated: September 18, 2009
Health Authority: Canada: Ethics Review Committee

Keywords provided by Sir Mortimer B. Davis - Jewish General Hospital:
lactase
lactose
microflora

Additional relevant MeSH terms:
Lactose Intolerance
Carbohydrate Metabolism, Inborn Errors
Digestive System Diseases
Gastrointestinal Diseases
Genetic Diseases, Inborn
Intestinal Diseases
Malabsorption Syndromes
Metabolic Diseases
Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on October 29, 2014